Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | HCK | P08631 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.47 |
| ▸ | PRKDC | P78527 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | BUB1 | O43683 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13247916 | 0.89 | PIK3CD (0.51) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL10193516 | 0.88 | BUB1 (0.40) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1273077 | 0.85 | HTR6 (0.49) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL819797 | 0.84 | PIK3CD (0.46) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL2006239 | 0.84 | OXER1 (0.50) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL18805035 | 0.84 | PIK3CD (0.46) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1454498 | 0.84 | PIK3CD (0.46) | PIK3CDABL1EGFRHCKSRC | |
| Methane SCHEMBL6390810 | 0.84 | HTR6 (0.48) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL312329 | 0.84 | PIK3CD (0.51) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL29829168 | 0.84 | OXER1 (0.50) | PIK3CDABL1EGFRHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2021046183-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20200277268-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2020-09-03 | — | — | US | disclosed |
| WO-2019056120-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2019-03-28 | — | — | WO | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9758453-B2 | One-component reagent for the fluoroalkylation reaction | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170158598-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20110312903-A1 | FLUORINATION OF ORGANIC COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2011-12-22 | — | — | US | disclosed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | disclosed |
| EP-1349857-B1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2010-06-16 | — | — | EP | disclosed |
| US-7452894-B2 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-11-18 | — | — | US | disclosed |
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2006-11-30 | — | — | US | disclosed |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-27 | — | — | US | disclosed |
| EP-1349857-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055521-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| EP-0429257-A2 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1991-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | PER2, CRY1, BACE1 | PIK3CD 2546/4885ABL1 2726/4885EGFR 4837/4885 |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | PIK3CD 1761/4885ABL1 337/4885EGFR 2283/4885 |
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | CHRNA10, CHRNA5, CHRNA4 | PIK3CD 2650/4885ABL1 3201/4885EGFR 3523/4885 |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | PIK3CD 509/4885ABL1 111/4885EGFR 147/4885 |
| US-20170158598-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | ACHE, DDT, PTMS | PIK3CD 480/4885ABL1 3506/4885EGFR 4579/4885 |
| US-20110312903-A1 | FLUORINATION OF ORGANIC COMPOUNDS | SLCO1B3, SLCO2B1, FLI1 | PIK3CD 3442/4885ABL1 90/4885EGFR 933/4885 |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | OPRL1, CNR1, CNR2 | PIK3CD 2582/4885ABL1 3445/4885EGFR 3108/4885 |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | CHEK1, CHEK2, BUB1 | PIK3CD 499/4885ABL1 345/4885EGFR 525/4885 |
| US-20200277268-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKI67, PKD1, ETV6 | PIK3CD 1564/4885ABL1 112/4885EGFR 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.